AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. CRWV
8. CME
9. ADBE
10. HUMA

Go back to AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
AbbVie (NYSE: ABBV) Delayed: 224.77 -0.18 (0.08%)
Previous Close $224.95    52 Week High $68.12 
Open $226.01    52 Week Low $50.71 
Day High $227.55    P/E 48.76 
Day Low $224.04    EPS $4.61 
Volume 4,569,346